CHRS Coherus BioSciences Inc

Price (delayed)

$14.14

Market cap

$1.07B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.02

Enterprise value

$1.23B

Sector: Healthcare
Industry: Biotechnology

Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients' lives and to deliver significant savings ...

Highlights

The net income has plunged by 158% from the previous quarter and by 152% YoY
Coherus BioSciences's EPS has shrunk by 155% QoQ and by 149% YoY

Key stats

What are the main financial stats of CHRS
Market
Shares outstanding
75.75M
Market cap
$1.07B
Enterprise value
$1.23B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.06
Price to sales (P/S)
2.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.77
Earnings
Revenue
$442.68M
EBIT
-$51.36M
EBITDA
-$46.14M
Free cash flow
$136.45M
Per share
EPS
-$1.02
Free cash flow per share
$1.87
Book value per share
$1.75
Revenue per share
$6.08
TBVPS
$9.47
Balance sheet
Total assets
$693.3M
Total liabilities
$565.63M
Debt
$414.27M
Equity
$127.67M
Working capital
$359.66M
Liquidity
Debt to equity
3.24
Current ratio
2.4
Quick ratio
2.1
Net debt/EBITDA
-3.35
Margins
EBITDA margin
-10.4%
Gross margin
91.3%
Net margin
-17.2%
Operating margin
-11.7%
Efficiency
Return on assets
-9.9%
Return on equity
-34.8%
Return on invested capital
-7.5%
Return on capital employed
-11.8%
Return on sales
-11.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CHRS stock price

How has the Coherus BioSciences stock price performed over time
Intraday
-6.54%
1 week
-0.98%
1 month
-1.74%
1 year
-14.92%
YTD
-18.64%
QTD
-3.22%

Financial performance

How have Coherus BioSciences's revenue and profit performed over time
Revenue
$442.68M
Gross profit
$404.36M
Operating income
-$51.91M
Net income
-$76.28M
Gross margin
91.3%
Net margin
-17.2%
The net margin has dropped by 162% since the previous quarter and by 151% year-on-year
The net income has plunged by 158% from the previous quarter and by 152% YoY
The company's operating margin has shrunk by 136% QoQ and by 131% YoY
The operating income has plunged by 133% from the previous quarter and by 131% YoY

Growth

What is Coherus BioSciences's growth rate over time

Valuation

What is Coherus BioSciences stock price valuation
P/E
N/A
P/B
8.06
P/S
2.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.77
Coherus BioSciences's EPS has shrunk by 155% QoQ and by 149% YoY
The equity has plunged by 55% from the previous quarter and by 19% YoY
The price to book (P/B) is 34% more than the last 4 quarters average of 6.0
The P/S is 97% below the 5-year quarterly average of 69.2 and 10% below the last 4 quarters average of 2.6
The revenue has declined by 7% since the previous quarter

Efficiency

How efficient is Coherus BioSciences business performance
CHRS's return on equity has dropped by 160% since the previous quarter and by 119% year-on-year
The return on assets has dropped by 154% since the previous quarter and by 125% year-on-year
Coherus BioSciences's return on sales has shrunk by 135% QoQ and by 130% YoY
CHRS's return on invested capital has dropped by 130% since the previous quarter and by 113% year-on-year

Dividends

What is CHRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CHRS.

Financial health

How did Coherus BioSciences financials performed over time
The total assets is 23% more than the total liabilities
The company's total liabilities has surged by 83% YoY
Coherus BioSciences's quick ratio has shrunk by 56% QoQ and by 31% YoY
The debt to equity has soared by 168% YoY and by 120% from the previous quarter
The debt has soared by 118% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.